Table 4.

Disease-free survival in RCTs.

First Author (year) or NCT record number [trial name]	Intergroup Difference			Intervention		Comparator
	Effect Estimate	95% CI	p-value	Treatment	Proportion	Treatment	Proportion (95% CI)
96-week (2 year) DFS
Kurebayashi 2017; NCT01546649	Difference: 1.2%	−5.2 - 7.8	NR	TAP-144-SR (6 month depot)	97.3% (95% CI: 93.6–100.0)	TAP-144-SR (3 month depot)	97.5% (95% CI: 94.1–100.0)
5-year DFS
Ruiz-Borrego (2019); NCT00543127 [GEICAM/2006–10]	NR	NR	NR	Anastrozole + fulvestrant	91.0% (95% CI: 88.2–93.9)	Anastrozole	90.8% (95% CI: 88.0–93.6)
Smith (2017) [FACE]	HR: 0.96	0.82–1.13	NR	Letrozole	84.7% (95% CI: 82.9–86.3)	Anastrozole	83.4% (95% CI: 81.6–85.1)
Tjan-Heijnen (2017)a [DATA]	HR: 0.79	0.61–1.03	NR	Anastrozole (6 years)	83.2% (95% CI: 79.7–86.7)	Anastrozole (3 years)	79.7% (95% CI: 76.2–83.3)
Colleoni (2018) [SOLE]	HR: 1.12	0.94–1.33	NR	Intermittent letrozole	85.0%	Continuous letrozole	86.6%
Francis (2015) [SOFT]	HR: 0.88	0.69–1.13	NR	Tamoxifen + OFS	86.3%b (95% CI: NR)	Tamoxifen	85.3%b (95% CI: NR)
7-year DFS
Ruiz-Borrego (2019); NCT00543127 [GEICAM/2006–10]	HR: 0.84	0.58–1.22	0.352	Anastrozole + fulvestrant	86.9% (95% CI: 83.3–90.6)	Anastrozole	83.3 (95% CI: 79.2–87.5)
8-year DFS
Filho (2015) [BIG 1–98]	HR for ILC: 0.48	0.31–0.74	NR	Letrozole	82% (95% CI: NR)	Tamoxifen	66% (95% CI: NR)
	HR for IDC: 0.80	0.68–0.94			82% (95% CI: NR)		75% (95% CI: NR)
10-year DFS
Derks (2017) [TEAM]	NR	NR	NR	Tamoxifen → exemestane	67% (95% CI: 66–69)	Exemestane	68% (95% CI: 66–70)

Abbreviations: CI = confidence interval; DFS = disease-free survival; HR = hazard ratio; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; NR = not reported; OFS = ovarian function suppression; RCT = randomized controlled trial.

^aStudy included patients who were disease-free after 3 years, as such the DFS outcome was termed 5-year “adapted” DFS.

^bReported in-text as proportion experiencing DFS events; subtracted from 100%.